ATKR LAWSUIT ALERT: Levi & Korsinsky Notifies Atkore Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Atkore Inc. (“Atkore Inc.” or the “Company”) (NYSE: ATKR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Atkore Inc. investors who were adversely affected by alleged securities fraud between August 2, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/atkore-inc-lawsuit-submission-form?prid=142236&wire=4

ATKR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, the Company and its price-fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result, defendants’ positive statements Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT’S NEXT? If you suffered a loss in Atkore Inc. during the relevant time frame, you have until April 23, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atkr-lawsuit-alert-levi–korsinsky-notifies-atkore-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302426102.html

SOURCE Levi & Korsinsky, LLP

FMC Corporation Class Action: Levi & Korsinsky Reminds FMC Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 – FMC

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in FMC Corporation (“FMC Corporation” or the “Company”) (NYSE: FMC) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of FMC Corporation investors who were adversely affected by alleged securities fraud between November 16, 2023 and February 4, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/fmc-corporation-lawsuit-submission-form?prid=142229&wire=4

FMC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company’s channel management initiatives were not progressing as represented; (2) faced with pricing pressure, the Company had made the decision not to compete on prices and instead walk away from sales opportunities; (3) the Company had inflated inventory in the channels in “Latin America, including Brazil, Asia, including India, as well as Canada and Eastern Europe;” and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in FMC Corporation during the relevant time frame, you have until April 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fmc-corporation-class-action-levi–korsinsky-reminds-fmc-corporation-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-14-2025–fmc-302426143.html

SOURCE Levi & Korsinsky, LLP

Zynex, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 19, 2025 to Discuss Your Rights – ZYXI

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Zynex, Inc. (“Zynex, Inc.” or the “Company”) (NASDAQ: ZYXI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=142248&wire=4

ZYXI investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) the Company’s practice of filing false claims drew scrutiny from insurers, including the U.S. military health insurance program, Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Zynex, Inc. during the relevant time frame, you have until May 19, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-inc-securities-fraud-class-action-lawsuit-pending-contact-levi–korsinsky-before-may-19-2025-to-discuss-your-rights–zyxi-302426169.html

SOURCE Levi & Korsinsky, LLP

Levi & Korsinsky Notifies Canopy Growth Corporation Investors of a Class Action Lawsuit and Upcoming Deadline – CGC

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Canopy Growth Corporation (“Canopy Growth Corporation” or the “Company”) (NASDAQ: CGC) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Canopy Growth Corporation investors who were adversely affected by alleged securities fraud between May 30, 2024 and February 6, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=142255&wire=4

CGC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (ii) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company’s gross margins and overall financial results; (iii) accordingly, defendants had overstated the efficacy of Canopy’s cost reduction measures and the health of its gross margins while downplaying issues with the same; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Canopy Growth Corporation during the relevant time frame, you have until June 3, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-canopy-growth-corporation-investors-of-a-class-action-lawsuit-and-upcoming-deadline–cgc-302426159.html

SOURCE Levi & Korsinsky, LLP

Alarum Technologies Ltd. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights – ALAR

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Alarum Technologies Ltd. (“Alarum Technologies Ltd.” or the “Company”) (NASDAQ: ALAR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alarum Technologies Ltd. investors who were adversely affected by alleged securities fraud between March 14, 2024 and August 26, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/alarum-technologies-ltd-lawsuit-submission-form?prid=142231&wire=4

ALAR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company was less effective in retaining and/or expanding customer engagements than it had represented to investors; (ii) the foregoing would impair Alarum’s ability to generate consistent revenue growth; (iii) accordingly, Alarum’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Alarum Technologies Ltd. during the relevant time frame, you have until April 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alarum-technologies-ltd-sued-for-securities-law-violations–investors-should-contact-levi–korsinsky-before-april-15-2025-to-discuss-your-rights–alar-302426149.html

SOURCE Levi & Korsinsky, LLP

Investors who lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class Action – MRK

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. (“Merck” or the “Company”) (NYSE: MRK) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142228&wire=4

MRK investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030. Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil’s growth in China. The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” Following this news, Merck’s common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck’s stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Merck during the relevant time frame, you have until April 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-who-lost-money-on-merck–co-incmrk-should-contact-levi–korsinsky-about-pending-class-action—mrk-302426139.html

SOURCE Levi & Korsinsky, LLP

Shareholders of Ultra Clean Holdings, Inc. Should Contact Levi & Korsinsky Before May 23, 2025 to Discuss Your Rights – UCTT

PR Newswire


NEW YORK
, April 11, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Ultra Clean Holdings, Inc. (“Ultra Clean” or the “Company”) (NASDAQ: UCTT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultra Clean investors who were adversely affected by alleged securities fraud between May 6, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/ultra-clean-holdings-inc-lawsuit-submission-form?prid=142251&wire=4

UCTT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning the elevated demand from Chinese original equipment manufacturers (OEMs) and in the general Chinese domestic market for Ultra Clean’s products throughout the fiscal year 2024. Defendants’ statements included, among other things, reports of increased demand for the Company’s products and services in the domestic Chinese market and reports of increased revenue, including revenue doubling with no signs of slowing down, due to the elevated demand in China for Ultra Clean’s products and services.  Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the demand for Ultra Clean’s products and services in the domestic Chinese market; notably, that the Company was facing a customer ramp issue with one of its critical customers, as well as a combination of inventory and demand corrections, which, ultimately, caused weakness for Ultra Clean in China.  On February 24, 2025, Ultra Clean published fourth quarter and full year 2024 fiscal results and hosted an associated earnings call, where the Company’s executives revealed that Ultra Clean was facing “demand softness” in China. In particular, Ultra Clean was facing decreased demand in China due to extended qualification timelines and inventory absorption.  Investors and analysts reacted immediately to these revelations. The price of Ultra Clean’s common stock declined dramatically. From a closing market price of $36.06 per share on February 24, 2025, Ultra Clean’s stock price fell to $25.90 per share on February 25, 2025, a decline of over 28% in the span a single day.

WHAT’S NEXT? If you suffered a loss in Ultra Clean during the relevant time frame, you have until May 23, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-of-ultra-clean-holdings-inc-should-contact-levi–korsinsky-before-may-23-2025-to-discuss-your-rights–uctt-302426153.html

SOURCE Levi & Korsinsky, LLP

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.” Negulescu shares the award with Michael J. Welsh, M.D., University of Iowa.

“For more than 20 years, Paul and the team of dedicated Vertex researchers have focused on discovering and developing breakthrough therapies for people living with cystic fibrosis (CF). Paul’s outstanding vision, leadership, determination and collaborative nature has resulted in what was once thought impossible — the discovery of the first-ever protein folding corrector medicines that treat the underlying cause of CF and have forever transformed the course of this disease,” said David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer at Vertex.

“I am honored and humbled by this award that recognizes not only me, but also the dedication, creativity and scientific excellence of the thousands of people across Vertex, and in the CF community, who have been steadfast in their commitment to bringing these medicines to people with cystic fibrosis around the world,” said Negulescu.

The gene responsible for CF was discovered in 1989, but until the work of Vertex scientists led by Negulescu, treatments for CF addressed only its symptoms rather than the underlying cause of disease. Today, Vertex’s five approved medicines treat CF by restoring function of the defective CFTR protein. The most recently approved medicine is a triple combination therapy that has the potential to treat more than 90% of people with CF with any of more than 300 different mutations, with once-daily dosing. The research team continues its relentless efforts to discover and develop even more effective therapies as well as novel approaches for the approximately 10% of people who are not expected to respond to existing therapies, such as a messenger ribonucleic acid (mRNA) approach currently in clinical development.

Through the Canada Gairdner International Award, the Gairdner Foundation, celebrates the world’s most creative and accomplished researchers whose unique scientific contributions have increased the understanding of human biology and disease, and improved the health and wellbeing of people around the world. The Canada Gairdner International Award is one of the most preeminent science awards in Canada and is widely recognized as one of the top scientific prizes in the world.

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 94,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving.

Today Vertex CF medicines are treating over 68,000 people with CF across 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 15 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work For.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: Europe United States North America Canada Massachusetts

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Managed Care Health Genetics Clinical Trials

MEDIA:

Logo
Logo

Weibo to Hold Annual General Meeting on May 20, 2025

PR Newswire


BEIJING
, April 11, 2025 /PRNewswire/ — Weibo Corporation (the “Weibo” or “Company”) (Nasdaq: WB and HKEX: 9898), China’s leading social media platform, today published a notice to announce that it will hold an annual general meeting (the “AGM”) of shareholders (the “Notice of AGM”) at 5809-5810, Two International Finance Centre, 8th Finance Street, Central, Hong Kong on Tuesday, May 20, 2025 at 2:00 p.m. (Hong Kong time), for the purposes of considering and, if thought fit, passing the proposed resolutions set forth in the Notice of AGM. The Notice of AGM and proxy card for the AGM are available on the Company’s website at ir.weibo.com. The board of directors of Weibo fully supports the proposed resolutions listed in the Notice of AGM and recommends that shareholders and holders of ADSs vote in favor of the resolutions set out in the Notice of AGM.

Holders of record of Class A ordinary shares of the Company (the “Class A Ordinary Shares”) and Class B ordinary shares of the Company at the close of business on April 30, 2025, Hong Kong time, are entitled to attend and vote at the AGM and any adjourned meeting thereof. Holders of record of American Depositary Shares (the “ADSs”) as of the close of business on April 30, 2025, New York time, who wish to exercise their voting rights for the underlying Class A Ordinary Shares must give voting instructions to JPMorgan Chase Bank, N.A., the depositary of the ADSs. 

Weibo’s Form 20-F can be accessed on the Company’s website at ir.weibo.com, as well as on the SEC’s website at http://www.sec.gov.

About Weibo

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. Weibo generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. We are continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology, such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “confidence,” “estimates” and similar statements. Weibo may also make written or oral forward-looking statements in the Company’s periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in announcements, circulars or other publications made on the website of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, Weibo’s limited operating history in certain new businesses; failure to sustain or grow active user base and the level of user engagement; the uncertain regulatory landscape in China; fluctuations in the Company’s quarterly operating results; the Company’s reliance on advertising and marketing sales for a majority of its revenues; failure to successfully develop, introduce, drive adoption of or monetize new features and products; failure to compete effectively for advertising and marketing spending; failure to successfully integrate acquired businesses; risks associated with the Company’s investments, including equity pick-up and impairment; failure to compete successfully against new entrants and established industry competitors; changes in the macro-economic environment, including the depreciation of the Renminbi; and adverse changes in economic and political policies of the PRC government and its impact on the Chinese economy. Further information regarding these and other risks is included in Weibo’s annual reports on Form 20-F and other filings with the SEC and the Hong Kong Stock Exchange. All information provided in this press release is current as of the date hereof, and Weibo assumes no obligation to update such information, except as required under applicable law.

Contacts

Investors Relations
Weibo Corporation
Tel: +86-10-5898-3336
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/weibo-to-hold-annual-general-meeting-on-may-20-2025-302426431.html

SOURCE Weibo Corporation

Yiren Digital’s “Zhiyu Large Model” Gains Regulatory Approval for Commercial Use, Marking New Milestone in AI Innovation

PR Newswire


BEIJING
, April 11, 2025 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) (“Yiren Digital”), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China, today announced that its proprietary “Zhiyu Large Model” (智语大模型) has received regulatory approval for commercialization through the successful filing under Interim Measures for the Management of Generative Artificial Intelligence Services. This milestone highlights Yiren Digital’s leadership in AI innovation, enabling the commercial deployment of secure and efficient intelligent solutions across diverse business applications.

The Zhiyu Large Model, a versatile foundation model, leverages Yiren Digital’s advanced AI capabilities to deliver a range of solutions, including real-time content processing and analysis, automated contract review, multilingual translation, intelligent Q&A and code generation capabilities. These features have been integrated into the company’s core workflows such as meeting management, legal document review, and tax/financial operations, driving measurable efficiency gains and fostering a smarter digital workplace.

Building on this success, Yiren Digital will actively broaden the model’s applications across diverse business scenarios, with particular focus on enhancing consumer-facing (2C) interactions. The goal is to deliver more natural and human-like engagement through AI-powered interfaces. Future integration with customer service systems will further elevate responsiveness and overall service quality.

Since its inception, Yiren Digital has consistently prioritized technological innovation and has developed a suite of seven proprietary AI systems that form the backbone of its operations, including the DiTing intelligent decision-making system, LingShu intelligent marketing platform, QingNiao smart customer service solution, and ZhuQue intelligent fund routing platform. The ZhuQue platform exemplifies the company’s technological prowess, employing sophisticated algorithms to optimize fund allocation based on dynamic analysis of borrower credit profiles, partner risk parameters, and cost structures. This system alone generated annual cost savings of RMB 44 million for the year 2024. With the commercial approval of the Zhiyu Large Model, Yiren Digital anticipates accelerated enhancement of its existing systems and smoother realization of its comprehensive AI commercialization strategy.

The regulatory approval positions Yiren Digital among an elite group of innovators. As of April 10, 2025, only 128 generative AI services in Beijing had successfully completed the filing process. Earlier this year, Yiren Digital became a member of China’s Artificial Intelligence Industry Alliance (AIIA), recognized for its cutting-edge advancements in AI development and applications. The company was also recognized among 2024 “Beijing’s Top 100 Software and Information Services Enterprises” and won the 2024 “Golden FinTech” Excellence Award by CAICT.

About Yiren Digital

Yiren Digital Ltd. is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Our mission is to elevate customers’ financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. We support clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

Cision View original content:https://www.prnewswire.com/news-releases/yiren-digitals-zhiyu-large-model-gains-regulatory-approval-for-commercial-use-marking-new-milestone-in-ai-innovation-302426443.html

SOURCE Yiren Digital